Cingulate(NASDAQ) CINGW

Market CapN/A

Since IPO (2021)-99%

5 YearN/A

1 Year-81%

1 Month-28%

$0.01

+53.23%

+0.00Today

Cingulate last closing stock price
Metric	Price	Date
Last close	USD 0.01	2026-08-31

Cingulate stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-16.67%	USD 0.01	2026-08-24
1 month	-28.03%	USD 0.01	2026-07-31
3 month	-62.75%	USD 0.03	2026-06-02
Year to date	-82.63%	USD 0.05	2025-12-31
1 year	-81%	USD 0.05	2025-08-28
3 year	-92.17%	USD 0.12	2023-09-01
Since inception	-99.05%	USD 1.00	2021-12-08

Cingulate Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$28.80M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.01

Volume

261

Open

$0.01

Price

$0.01

Volume

261

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.12

Estimated Earnings Date

Nov 18, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.01

Volume

261

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.12

Estimated Earnings Date

Nov 18, 2026

CINGW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cingulate

Cingulate Inc. is a biopharmaceutical firm focused on developing innovative therapies for central nervous system and neurobiological conditions. The company is advancing its lead investigational medicines, CTx-1301 and CTx-1302, aimed at managing attention deficit/hyperactivity disorders (ADHD), along with CTx-2103 for anxiety disorders.

Products and Services

CTx-1301: A novel formulation of dexmethylphenidate for ADHD management
CTx-1302: A dextroamphetamine formulation targeting ADHD symptoms
CTx-2103: An investigational treatment for anxiety disorders

Growth Outlook

Strong pipeline with multiple investigational therapies in development
Increasing demand for ADHD and anxiety disorder treatments
Potential for strategic partnerships to enhance market reach

Financial Highlights

Cash and cash equivalents of $28.4 million as of June 30, 2026
Operating expenses of $5.4 million reported in Q2 2026
Net income of -$5.9 million for Q2 2026, reflecting ongoing R&D investments

Cingulate Inc. operates in a promising sector with a focus on unmet medical needs. The company's commitment to developing effective treatments for ADHD and anxiety disorders positions it well for future growth. With a solid cash position, Cingulate is poised to continue its research and development efforts, potentially leading to significant advancements in the biopharmaceutical landscape. The ongoing investments in innovative therapies may attract interest from investors looking for opportunities in the healthcare sector.

AI Generated • Aug 31, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Kansas City, KS 66205, US

CINGW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-238.41%

Return on Capital

-176.51%

Return on Assets

-87.09%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

261

Avg. Volume

17.92K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$24.92M

EBITDA

$194.42M

Operating Cash Flow

-$20.65M

Capital Expenditure

-$284.46K

Free Cash Flow

-$20.94M

Cash & ST Invst.

$28.40M

Total Debt

$6.29M

Cingulate Performance Analysis

Cingulate sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A
Q2	2026-06-30	N/A

Cingulate sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-23.9%
Q4	2025-12-31	35.6%
Q1	2026-03-31	-96.6%
Q2	2026-06-30	36.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$5.87M

-22.6%

EBITDA

$213.58M

+4843.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$28.40M

+219.1%

Total Debt

$6.29M

-4.4%

Accounts Receivable

$38.45K

+96.3%

Inventory

$0.00

N/A

Long Term Debt

$968.46K

-20.9%

Short Term Debt

$5.32M

-0.7%

Return on Assets

-87.09%

N/A

Return on Invested Capital

-1.02%

N/A

Free Cash Flow

-$5.97M

-24.3%

Operating Cash Flow

-$5.90M

-23.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KALAKALA BIO, Inc.

KALAKALA BIO, Inc.$0.67-2.52%

PHIOPhio Pharmaceuticals Corp.

PHIOPhio Pharmaceuticals Corp.$1.09-3.54%

APVOAptevo Therapeutics Inc.

APVOAptevo Therapeutics Inc.$2.44+3.17%

COCPCocrystal Pharma, Inc.

COCPCocrystal Pharma, Inc.$1.16+5.45%

ERNAErnexa Therapeutics Inc.

ERNAErnexa Therapeutics Inc.$4.57+0.00%

TVGNTevogen Bio Holdings Inc.

TVGNTevogen Bio Holdings Inc.$6.98+1.31%

BOLTBolt Biotherapeutics, Inc.

BOLTBolt Biotherapeutics, Inc.$3.98+4.19%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About CINGW

What is the current price of Cingulate?

Cingulate is trading at $0.01 per share.

What is the 52-week range for Cingulate?

Over the past 52 weeks, Cingulate has traded between $0.00 and $0.12.

How much debt does Cingulate have?

Cingulate total debt is unavailable.

How much cash does Cingulate have on hand?

Cingulate does not have cash on hand data available.

What is Cingulate’s dividend yield?

Cingulate does not currently have a dividend yield.

Cingulate(NASDAQ) CINGW

Cingulate Financials at a Glance

CINGW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cingulate

CINGW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cingulate Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CINGW

What is the current price of Cingulate?

What is the 52-week range for Cingulate?

How much debt does Cingulate have?

How much cash does Cingulate have on hand?

What is Cingulate’s dividend yield?

Premium Investing Services